BSL02 150929Y

Drug Profile

BSL02 150929Y

Alternative Names: BSL02-150929Y

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kao Corporation
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Erythema

Most Recent Events

  • 29 Sep 2016 Kao Corporation completes a phase-I clinical trial in Erythema (Prevention) in Japan (Topical) (UMIN000019152)
  • 26 Oct 2015 Phase-I clinical trials in Erythema (Prevention) in Japan (Topical) (UMIN000019152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top